Patents Assigned to CELLECTAR BIOSCIENCES, INC.
  • Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells
    Patent number: 11467159
    Abstract: The present invention is directed to a method of identifying, isolating, and enabling downstream analysis of circulating tumor cells comprising contacting a blood or blood serum sample of a subject with a composition comprising a phospholipid ether analog bound to a luminescent molecule or a magnetic bead and subjecting the blood or blood serum sample of the subject to fluorescent microscopy, flow cytometry or magnetic isolation.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: October 11, 2022
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Chorom Pak, Anatoly Pinchuk, Kevin Kozak, Marc Longino
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 11439709
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: September 13, 2022
    Assignee: Cellectar Biosciences, Inc.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer Therapy
    Publication number: 20210163513
    Abstract: Disclosed herein are phospholipid ether (PLE) molecules. Further provided are phospholipid-flavagline conjugates. The phospholipid-flavagline conjugate may include a PLE conjugated to a flavagline via a linker. Further provided herein are methods of treating cancer in a subject and methods of targeting a drug to a tumor or cancer cell in a subject.
    Type: Application
    Filed: April 10, 2019
    Publication date: June 3, 2021
    Applicant: Cellectar Biosciences, Inc.
    Inventor: Jarrod LONGCOR
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9925269
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: March 27, 2018
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Fluorescent phospholipid ether compounds, compositions, and methods of use
    Patent number: 9616140
    Abstract: The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: April 11, 2017
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino, Irawati Kandela, William R. Clarke
  • Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
    Patent number: 9579406
    Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 28, 2017
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
  • Phospholipid analogs as diapeutic agents and methods thereof
    Patent number: 9550002
    Abstract: The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 24, 2017
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9480754
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 1, 2016
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9345718
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 24, 2016
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle